DECIPHERA PHARMACEUTICALS IN (DCPH) Fundamental Analysis & Valuation

NASDAQ:DCPH • US24344T1016

Current stock price

25.59 USD
+0.02 (+0.08%)
At close:
25.61 USD
+0.02 (+0.08%)
After Hours:

This DCPH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. DCPH Profitability Analysis

1.1 Basic Checks

  • In the past year DCPH has reported negative net income.
  • In the past year DCPH has reported a negative cash flow from operations.
  • In the past 5 years DCPH always reported negative net income.
  • In the past 5 years DCPH always reported negative operating cash flow.
DCPH Yearly Net Income VS EBIT VS OCF VS FCFDCPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -100M -200M -300M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -45.24%, DCPH is in line with its industry, outperforming 52.53% of the companies in the same industry.
  • DCPH has a Return On Equity of -60.25%. This is comparable to the rest of the industry: DCPH outperforms 58.99% of its industry peers.
Industry RankSector Rank
ROA -45.24%
ROE -60.25%
ROIC N/A
ROA(3y)-50.14%
ROA(5y)-44.56%
ROE(3y)-68.79%
ROE(5y)-58.11%
ROIC(3y)N/A
ROIC(5y)N/A
DCPH Yearly ROA, ROE, ROICDCPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

  • DCPH's Gross Margin of 96.95% is amongst the best of the industry. DCPH outperforms 97.91% of its industry peers.
  • DCPH's Gross Margin has been stable in the last couple of years.
  • DCPH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.95%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.59%
GM growth 5YN/A
DCPH Yearly Profit, Operating, Gross MarginsDCPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. DCPH Health Analysis

2.1 Basic Checks

  • DCPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • DCPH has more shares outstanding than it did 1 year ago.
  • DCPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
DCPH Yearly Shares OutstandingDCPH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
DCPH Yearly Total Debt VS Total AssetsDCPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 7.32 indicates that DCPH is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 7.32, DCPH belongs to the top of the industry, outperforming 83.07% of the companies in the same industry.
  • There is no outstanding debt for DCPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.32
ROIC/WACCN/A
WACC8.89%
DCPH Yearly LT Debt VS Equity VS FCFDCPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

  • DCPH has a Current Ratio of 4.19. This indicates that DCPH is financially healthy and has no problem in meeting its short term obligations.
  • DCPH has a Current ratio (4.19) which is comparable to the rest of the industry.
  • DCPH has a Quick Ratio of 3.94. This indicates that DCPH is financially healthy and has no problem in meeting its short term obligations.
  • DCPH's Quick ratio of 3.94 is in line compared to the rest of the industry. DCPH outperforms 44.15% of its industry peers.
Industry RankSector Rank
Current Ratio 4.19
Quick Ratio 3.94
DCPH Yearly Current Assets VS Current LiabilitesDCPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. DCPH Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 5.96% over the past year.
  • DCPH shows a strong growth in Revenue. In the last year, the Revenue has grown by 26.51%.
  • The Revenue has been growing by 57.16% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)5.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.33%
Revenue 1Y (TTM)26.51%
Revenue growth 3Y57.16%
Revenue growth 5YN/A
Sales Q2Q%27.22%

3.2 Future

  • Based on estimates for the next years, DCPH will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.21% on average per year.
  • The Revenue is expected to grow by 25.42% on average over the next years. This is a very strong growth
EPS Next Y5.08%
EPS Next 2Y14.35%
EPS Next 3Y20.37%
EPS Next 5Y18.21%
Revenue Next Year25.31%
Revenue Next 2Y26.97%
Revenue Next 3Y32.58%
Revenue Next 5Y25.42%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
DCPH Yearly Revenue VS EstimatesDCPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
DCPH Yearly EPS VS EstimatesDCPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4 -4

More info and screens

Find the best growth stocksShow best growing peers

1

4. DCPH Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for DCPH. In the last year negative earnings were reported.
  • Also next year DCPH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DCPH Price Earnings VS Forward Price EarningsDCPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DCPH Per share dataDCPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

  • DCPH's earnings are expected to grow with 20.37% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.35%
EPS Next 3Y20.37%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DCPH Dividend Analysis

5.1 Amount

  • No dividends for DCPH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

DCPH Fundamentals: All Metrics, Ratios and Statistics

DECIPHERA PHARMACEUTICALS IN

NASDAQ:DCPH (6/10/2024, 8:00:00 PM)

After market: 25.61 +0.02 (+0.08%)

25.59

+0.02 (+0.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-10
Earnings (Next)08-07
Inst Owners6.97%
Inst Owner Change0%
Ins Owners26.79%
Ins Owner Change0%
Market Cap2.21B
Revenue(TTM)174.91M
Net Income(TTM)-190.42M
Analysts71.25
Price Target27.25 (6.49%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.41%
Min EPS beat(2)8.03%
Max EPS beat(2)8.79%
EPS beat(4)4
Avg EPS beat(4)8.32%
Min EPS beat(4)6.6%
Max EPS beat(4)9.87%
EPS beat(8)7
Avg EPS beat(8)5.71%
EPS beat(12)8
Avg EPS beat(12)3.61%
EPS beat(16)12
Avg EPS beat(16)5.04%
Revenue beat(2)1
Avg Revenue beat(2)-3.37%
Min Revenue beat(2)-9.86%
Max Revenue beat(2)3.11%
Revenue beat(4)3
Avg Revenue beat(4)1.42%
Min Revenue beat(4)-9.86%
Max Revenue beat(4)7.77%
Revenue beat(8)5
Avg Revenue beat(8)0.97%
Revenue beat(12)8
Avg Revenue beat(12)1.76%
Revenue beat(16)12
Avg Revenue beat(16)51.69%
PT rev (1m)1.26%
PT rev (3m)17.06%
EPS NQ rev (1m)9.43%
EPS NQ rev (3m)8.94%
EPS NY rev (1m)1.43%
EPS NY rev (3m)3.18%
Revenue NQ rev (1m)2.15%
Revenue NQ rev (3m)1.7%
Revenue NY rev (1m)0.68%
Revenue NY rev (3m)0.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.65
P/FCF N/A
P/OCF N/A
P/B 7
P/tB 7
EV/EBITDA N/A
EPS(TTM)-2.21
EYN/A
EPS(NY)-1.59
Fwd EYN/A
FCF(TTM)-1.76
FCFYN/A
OCF(TTM)-1.76
OCFYN/A
SpS2.02
BVpS3.65
TBVpS3.65
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -45.24%
ROE -60.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.95%
FCFM N/A
ROA(3y)-50.14%
ROA(5y)-44.56%
ROE(3y)-68.79%
ROE(5y)-58.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.59%
GM growth 5YN/A
F-Score4
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 29.04%
Cap/Sales 0.32%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.19
Quick Ratio 3.94
Altman-Z 7.32
F-Score4
WACC8.89%
ROIC/WACCN/A
Cap/Depr(3y)87.89%
Cap/Depr(5y)217.78%
Cap/Sales(3y)2.44%
Cap/Sales(5y)7.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.33%
EPS Next Y5.08%
EPS Next 2Y14.35%
EPS Next 3Y20.37%
EPS Next 5Y18.21%
Revenue 1Y (TTM)26.51%
Revenue growth 3Y57.16%
Revenue growth 5YN/A
Sales Q2Q%27.22%
Revenue Next Year25.31%
Revenue Next 2Y26.97%
Revenue Next 3Y32.58%
Revenue Next 5Y25.42%
EBIT growth 1Y-9.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year5.52%
EBIT Next 3Y4.87%
EBIT Next 5YN/A
FCF growth 1Y33.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.37%
OCF growth 3YN/A
OCF growth 5YN/A

DECIPHERA PHARMACEUTICALS IN / DCPH Fundamental Analysis FAQ

What is the fundamental rating for DCPH stock?

ChartMill assigns a fundamental rating of 4 / 10 to DCPH.


What is the valuation status of DECIPHERA PHARMACEUTICALS IN (DCPH) stock?

ChartMill assigns a valuation rating of 1 / 10 to DECIPHERA PHARMACEUTICALS IN (DCPH). This can be considered as Overvalued.


Can you provide the profitability details for DECIPHERA PHARMACEUTICALS IN?

DECIPHERA PHARMACEUTICALS IN (DCPH) has a profitability rating of 2 / 10.


What is the financial health of DECIPHERA PHARMACEUTICALS IN (DCPH) stock?

The financial health rating of DECIPHERA PHARMACEUTICALS IN (DCPH) is 7 / 10.